Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04447943 in stable sickle cell disease
NCT02114203Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of edelinontrine in sickle cell disease (SCD) (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Vital Signs at Day 29, Number of Participants With Potentially Clinically Important (PCI) Change From Baseline in Neurologic Function at Day 29 and 5 more. Started Dec 2014; status: completed.
02
Drugs
edelinontrine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02114203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114203.